Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLAR: 64Cu-PSMA I&T in Metastatic Prostate Cancer
NCT05653856Phase 2Completed
- Sponsor
- Curium
- Start
- Dec 2022
- Primary completion
- May 2023
- Modality
- Radiopharmaceutical, CA (Contrast Agent)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of copper Cu 64 PSMA I&T in prostate cancer (PCa), sponsored by Curium. Primary endpoints: Region-Level Correct Localization Rate at 4 hours, Patient-Level Correct Detection Rate at 4 hours and 1 more. Started Dec 2022; status: completed.
02
Drugs
copper Cu 64 PSMA I&T
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05653856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05653856.